Actavis plc has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash. 

Actavis currently markets approximately a dozen products through local distributors in Thailand and has approximately nine additional products under registration. The combination is anticipated to result in opportunities to expand the core therapeutic areas of cardiovascular, ophthalmology, and respiratory with complementary and novel products as well as the potential to use Silom Medical’s sales channels to create opportunities in new therapeutic categories, including oncology, women’s health, central nervous system, and other areas.

Silom Medical offers more than 25 products in various dosage forms to more than 4400 hospitals, clinics and drugstores throughout the country. The company has an experienced, in-house sales force and operates a 32,000-square meter manufacturing facility in Ayutthaya with a production capacity of 660 million tablets/capsules and 47 million sterile units per year. .

In other news, Actavis has successfully completed the divestiture of its generics commercial operations in seven markets in Western Europe to Aurobindo Pharma Limited. The agreement to divest the commercial operations was announced in January 2014. Aurobindo acquired Actavis’ pharmaceutical commercial infrastructure in France, Italy, Spain, Portugal, Belgium, Germany, and the Netherlands, including products, marketing authorizations, and dossier license rights. The two companies also entered into a long-term strategic supply arrangement.

Source: Actavis (Silom Medical acquisition)  and Actavis (Aurobindo Pharma transaction)